Working… Menu

An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00583713
Recruitment Status : Completed
First Posted : December 31, 2007
Results First Posted : November 1, 2010
Last Update Posted : November 11, 2010
Information provided by:
Braintree Laboratories

Brief Summary:
To evaluate and compare the effects on safety measures and clinical chemistry after BLI800 in two groups of patients and one group of healthy controls. The patient groups will be those with mild or moderate hepatic impairment or moderate renal disease.

Condition or disease Intervention/treatment Phase
Colonoscopy Bowel Preparation Drug: BLI-800 Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : August 2007
Actual Primary Completion Date : April 2008
Actual Study Completion Date : June 2008

Arm Intervention/treatment
Experimental: Renal Group
Patients with moderate renal impairment
Drug: BLI-800
BLI-800 oral solution (two doses)

Active Comparator: Healthy volunteers
Healthy volunteers
Drug: BLI-800
BLI-800 oral solution (two doses)

Experimental: Hepatic Group
Patients with mild/moderate hepatic impairment.
Drug: BLI-800
BLI-800 oral solution (two doses)

Primary Outcome Measures :
  1. Maximum Observed Concentration (Cmax) [ Time Frame: 1 day ]
  2. Time to Maximum Concentration [ Time Frame: 1 day ]
  3. Terminal Half-life [ Time Frame: 1 day ]
  4. Area Under the Curve for the 24-hour Dosing Interval [ Time Frame: 1 day ]
  5. Elimination Rate Constant [ Time Frame: 1 day ]

Secondary Outcome Measures :
  1. Urinary Sulfate Concentration [ Time Frame: pre-dose to 6 days post-dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Are male or female adults who are:

    • With Child-Pugh Hepatic Dysfunction Stage A or B, or
    • With Moderate Renal Disease or
    • Healthy subjects matched to those who are enrolled in this study
  • Subjects who are considered to have only clinically non-significant conditions, as judged by the Principal Investigator and based on physical examination, laboratory profiles, medical history and ECG.
  • Female subjects who are not surgically sterile (i.e., having had a hysterectomy, bilateral oophorectomy or tubal ligation) or who are not at least 2 years naturally postmenopausal must agree to use an acceptable form of contraception.
  • Provide voluntary consent in writing to participate in this study.

Exclusion Criteria:

  • Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects who, in the opinion of the Principal Investigator, have uncontrolled clinically significant pre-existing electrolyte disturbances, based on the Screening visit laboratory results.
  • Subjects with present or prior NYHA Functional Classification grade III or IV congestive heart failure.
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  • Subjects of childbearing potential who refuse a pregnancy test.
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.
  • Subjects with a history of allergic or adverse response to any BLI-800 component.
  • Subjects who donated more than one pint of blood within 30 days prior to the study.
  • Subjects who donated plasma within 7 days prior to the study.
  • Subjects who had an abnormal diet or substantial changes in eating habits within 30 days prior to the start of the study.
  • Subjects who have had a bowel cleansing procedure within the past month or who have taken a laxative within the 5 days (120 hours) prior to dosing or who require a laxative every day.
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00583713

Layout table for location information
United States, Minnesota
Minneapolis, Minnesota, United States
Sponsors and Collaborators
Braintree Laboratories
Layout table for investigator information
Study Director: Russell Pelham, Ph.D. Braintree Laboratories, Inc.
Layout table for additonal information
Responsible Party: Russell Pelham, Ph.D., Braintree Laboratories, Inc. Identifier: NCT00583713    
Other Study ID Numbers: BLI-800-202
First Posted: December 31, 2007    Key Record Dates
Results First Posted: November 1, 2010
Last Update Posted: November 11, 2010
Last Verified: October 2010